10:58 AM EDT, 05/20/2024 (MT Newswires) -- Ensysce Biosciences ( ENSC ) said Monday it renewed the collaboration with Quotient Sciences to undertake a study to evaluate examine and evaluate the full commercial dose range of PF614-MPAR.

The phase 1 trial will evaluate opioid release following administration of 25 milligrams, 50 milligrams and 100 milligrams doses twice a day for five days, Ensysce said.

The company said it is developing PF614-MPAR, a combination opioid painkiller that shuts off opioid release when too many pills are ingested, to protect against deliberate and accidental overdose.

Quotient Sciences' Translational Pharmaceutics platform will be used to manufacture and test PF614-MPAR to accelerate the clinical study, Ensysce said.

Ensysce shares rose 12% in recent trading Monday.

Price: 0.70, Change: +0.07, Percent Change: +11.86